A Phase 2 interventional study of CM310 in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 3rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5
First in 2020; this study’s year is marked. 2 started in 2021.
This study's enrollment of 127 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 12 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd: 4 open now, 5 under way, 3 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 9 in phase 2, and was the 3rd registered.
Keymed Biosciences Co.Ltd’s Dermatitis, Atopic studies by the year they started, since 2020.
1 of the studies testing stapokibart in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keymed Biosciences Co.Ltd’s 18 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in patients with atopic dermatitis (AD).
The secondary objective of the study is to assess the immunogenicity of CM310 in patients with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participation in a prior clinical trial of CM310 for AD(CM310AD001 and CM310AD002) and met one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC. teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.
Biological: CM310
adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC. teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.
Also known as: IL-4Rα monoclonal antibody
Number of Treatment Emergent Adverse Events (TEAEs)
The primary endpoint in the study is the incidence and rate (events per patient-year) of TEAEs
Time frame: Up to 2 Years
Number of Serious Adverse Events (SAEs) and Adverse Event of special interest(AESI)
Incidence and rate (events per patient-year) of SAEs and AESIs
Time frame: Up to 2 Years
Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75 percent reduction in EASI scores from baseline of the parent study) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to 2 Years
Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 and decline ≥2 points from baseline at each visit
Proportion of patients who achieve and maintain a score of 0 to 1 on the IGA scale \[(a 6-point scale ranging from 0 (clear) to 5 (very severe)\]
Time frame: Up to 2 Years
Proportion of patients with Eczema Area and Severity Index (EASI)-90 (≥90 percent reduction in EASI scores from baseline of the parent study) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to 2 Years
Proportion of patients with Eczema Area and Severity Index (EASI)-50 (≥50 percent reduction in EASI scores from baseline of the parent study) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to 2 Years
Change from baseline in EASI score at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to 2 Years
Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit
IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)
Time frame: Up to 2 Years
Proportion of patients with IGA reduction from baseline of ≥2 points at each visit
IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)
Time frame: Up to 2 Years
Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥4 points from baseline
Proportion of subjects with improvement (reduction) of pruritus NRS of ≥4 points from baseline. The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Up to 2 Years
Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥3 points from baseline
The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Up to 2 Years
Percent change from baseline in NRS
The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Up to 2 Years
Body Surface Area (BSA)
Change from baseline in percent of BSA
Time frame: Up to 2 Years
Time to first remission (achieving IGA = 0 or 1)
Time frame: Up to 2 Years
Time to first relapse (eg, IGA >2) after remission or to not achieving remission
Time frame: Up to 2 Years
Time to first EASI-50/75/90
Time frame: Up to 2 Years
Proportion of patients requiring rescue treatment: Overall/Systemic treatment/Immunosuppressor/Systemic treatment
Time frame: Up to 2 Years
Number of days on topical medication (per patient-year)
Time frame: Up to 2 Years
Changes from baseline to prespecified time points through the end of the study: Dermatology Life Quality Index (DLQI)
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL) (Badia 1999). The format is a simple response to 10 items, which assess QOL over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QOL
Time frame: Up to 2 Years
immunogenicity
Detection of anti-drug antibody (ADA)
Time frame: Up to 2 Years
Pharmacokinetics parameters
trough concentration of CM310
Time frame: Up to 2 Years
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Feb 2023, 19 months.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 19 months is above that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart